POSTER PRESENTATIONS SESSION III


Poster Session I Poster Session II Poster Session III
  • Health Care Use & Policy
  • Arthritis including skeletal issues

  • Diabetes

  • Endocrine Disorders

  • GI Disorders

  • Hematological Disorders

  • Individual’s Health

  • Respiratory Disorders

  • Skin

  • Methods & Concepts

  • Cancer

  • Infection

  • Mental Health

  • Obesity

  • Pain

  • Stroke

  • Surgery

 
 


ASTHMA/ALLERGY

Cost Studies 

PAA1

CLINICAL EFFECTIVENESS OF ADJUSTABLE DOSING SINGLE INHALER BUDESONIDE/FORMOTEROL FOR ASTHMA AND BUDGET IMPACT ANALYSIS

 

Kaczor M, Becla L, Wojcik R, Dardzinski W, Walczak J, Nogas G

 

Arcana Institute, Cracow, Poland

PAA2

EFFECT OF SUBLINGUAL IMMUNOTHERAPY (SLIT) ON DIRECT MEDICAL COSTS FOR PATIENTS WITH ALLERGIC RHINITIS AND ASTHMA: RESULTS FROM THE SIMAP DATABASE STUDY

 

Berto P1, Bassi M2, Cadario G3, Cantarutti L4, Contiguglia R5, Crivellaro M6, Di Gioacchino M7, Frati F8, Magazzů C5, Marengo F3, Scamarcia A4, Schiappoli M6, Valle C9, Verna N7, Giaquinto C10

 

1Pbe consulting, Verona, Italy, 2Rho Hospital, Cerchiate di Pero (MI), Italy, 3Azienda Ospedaliera S.Giovanni Battista di Torino (Molinette), Torino, Italy, 4SOSEPE, Padova, Italy, 5AUSL 5, Messina, Italy, 6Azienda Ospedaliera Verona, Verona, Italy, 7D'Annunzio University, Chieti, Italy, 8Stallergenes Italy, Milano, Italy, 9Ospedale San Paolo, Milano, Italy, 10University of Padova, Padova, Veneto, Italy

PAA3

COST OF MANAGING ASTHMA EXACERBATIONS WITH STABLE DOSING OF SALMETEROL/FLUTICASONE COMBINED PRODUCT (SFC) COMPARED WITH ADJUSTABLE MAINTENANCE DOSING (AMD) OF FORMOTEROL/ BUDESONIDE COMBINED PRODUCT (FBC) IN POLAND

 

Orlewska E1, Cel M2, Glogowski C2

 

1Centrum Farmakoekonomiki, Warsaw, Poland, 2GSK Commercial Sp. z o.o, Warsaw, Poland

PAA4

PHARMACOECONOMIC ANALYSIS OF USE OF A SIMBICORT TURBUHALER AND SERETIDE MULTIDISK OF ASTHMA PATIENTS

 

Kulikov A, Lomakin A, Krysanov I, Polivanov V

 

Moscow Medical Academy, Moscow, Russia

PAA5

ECONOMIC EVALUATION OF A NEW AIRWAY INFLAMMATION MONITOR IN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA IN GERMANY

 

Berg J1, Lindgren P1, Jönsson B2

 

1Stockholm Health Economics, Stockholm, Sweden, 2Stockholm School of Economics, Stockholm, Sweden

PAA6

VALUING REDUCED RATES OF OROPHARYNGEAL ADVERSE EVENTS: COMPARISON OF CICLESONIDE WITH FLUTICASONE PROPIONATE

 

Wlodarczyk JH1, Harvey C2, Caeser M3

 

1John Wlodarczyk Consulting Services, New Lambton, NSW, Australia, 2Altana Pharma Pty Ltd, NOrth Ryde, NSW, Australia, 3ALTANA Pharma AG, Konstanz, Germany

PAA7

ANALYZING THE INFLUENCE OF SWITCHING BETWEEN DIFFERENT ASTHMA REGIMES ON MEDICATION ADHERENCE TO ASTHMA THERAPY, RESOURCE UTILIZATION AND COSTS

 

Buesch K1, Welte R2, Singer C2

 

1GSF-National Research Center for Environment and Health, Neuherberg, Bavaria, Germany, 2GlaxoSmithKline, Munich, Germany

PAA8

A COMPARISON OF CLAIMS RATIO BETWEEN PRIMARY AND SECONDARY DRUGS IN THE MANAGEMENT OF ASTHMA. A CANADIAN ANALYSIS

 

Ciobanu A

 

AstraZeneca, Mississauga, ON, Canada

Health Care Use & Policy Studies

PAA9

THE EFFECTS OF GENERIC-ONLY DRUG COVERAGE ON INHALED CORTICOSTEROID EXPENDITURES AND USE

 

Fung V1, Fireman B1, Brand R2, Newhouse JP3, Hsu J1

 

1Kaiser Permanete, Oakland, CA, USA, 2University of California at San Francisco, San Francisco, CA, USA, 3Harvard University, Boston, MA, USA

PAA10

HEALTH PLAN STRUCTURE AND EXPENDITURES FOR ASTHMA CARE

 

Nurmagambetov T, Atherly A, Williams S, Redd S

 

Centers for Disease Control and Prevention, Atlanta, GA, USA

Methods & Concepts

PAA11

COST-EFFECTIVENESS ANALYSIS FOR THE ASSESSMENT OF PREVENTIVE SCHEMES BASED ON GENETIC SCREENING

 

Gutierrez de Mesa E1, Hidalgo I1, Christidis P1, Ciscar JC1, Vegas E2, Ibarreta D1

 

1Institute for Prospective Technological Studies, JRC-European Commission, seville, Spain, Spain, 2Servicio Madrleńo de Salud, Alcala de Henares. MADRID, Spain

Patient Reported Outcomes 

PAA12

THE EFFECT OF SWITCHING ON ADHERENCE TO DIFFERENT TYPES OF ASTHMA TREATMENT

 

Buesch K1, Singer C2, Welte R2

 

1GSF-National Research Center for Environment and Health, Neuherberg, Bavaria, Germany, 2GlaxoSmithKline, Munich, Germany

PAA13

OBTAINING POPULATION REFERENCE VALUES FOR THE ESPRINT-15 QUESTIONNAIRE, A SPECIFIC QUALITY OF LIFE SCALE FOR ALLERGIC RHINITIS (AR)

 

Valero A1, Monclús L2, Baro E3, on behalf of Esprint Study Investigators -4

 

1Hospital Clínic i Provincial de Barcelona, Barcelona, Spain, 2J. Uriach & Cia, S.A, Palau-solitŕ i plegamans, Barcelona, Spain, 33D Health Research, Barcelona, Spain, 4Esprint Study Investigators, Spain, Spain

PAA14

PATIENT-PERCEIVED SIDE EFFECTS OF CICLESONIDE AS COMPARED TO FLUTICASONE PROPIONATE IN THE TREATMENT OF MODERATE ASTHMA USING THE INHALED CORTICOSTEROID QUESTIONNAIRE

 

van der Molen T1, Leichtl S2, Caeser M2

 

1University of Groningen, Groningen, The Netherlands, 2ALTANA Pharma AG, Konstanz, Germany

PAA15

THE CONSTRUCT VALIDITY AND TEST-RETEST RELIABILITY OF THE INHALED CORTICOSTEROID QUESTIONNAIRE (ICQ): A PATIENT SELF-REPORTED SIDE EFFECT SCALE

 

Foster JM1, Van Sonderen E1, Lee AJ2, Sanderman R1, Van der Molen T1

 

1University of Groningen, Groningen, The Netherlands, 2University of Aberdeen, Aberdeen, UK


CARDIOVASCULAR

Clinical Outcomes Studies

PCV1

CLINICAL IMPACT OF DIAGNOSTIC IMAGING OF LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE

 

Scranton R1, Dhingra R1, Lawler E2, Hay JW3, Yucel K2, Guo A4, Balzer T4, Gaziano J1

 

1VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA, 2VA Boston Healthcare System, Boston, MA, USA, 3University of Southern California, Los Angeles, CA, USA, 4Berlex Laboratories, Wayne, NJ, USA

PCV2

CARDIOVASCULAR RISK FACTORS IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN 5 EUROPEAN COUNTRIES

 

McCollam PL1, Nasuti P2, Bae JP1, Smith H2

 

1Eli Lilly and Company, Indianapolis, IN, USA, 2IMS Hospital Group Ltd, Sittingbourne, UK

PCV3

DO WE FOLLOW THE GUIDELINES ON PREVENTION OF CARDIOVASCULAR DISEASE IN OUT-PATIENT CARE ?

 

Pietrasik A1, Starczewska M1, Glowczynska R1, Opolski G1, Filipiak KJ1, Jakubczyk M2, Niewada M1, Latek M3

 

1Medical University of Warsaw, Warsaw, Poland, 2Warsaw School of Economics, Warsaw, Poland, 3Warsaw School of Economics, Warszawa, Poland

PCV4

META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF PRESSURE MEASUREMENTS IN CORONARY ARTERY DISEASE

 

Bornschein B1, Klauss V2, Siebert U1

 

1UMIT University of Health Sciences, Medical Informatics, and Technology, Hall i. T, Austria, 2University of Munich, Munich, Germany

PCV5

DRUG-ELUTING STENT USE IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN LONG-TERM CLINICAL OUTCOMES

 

Eisenstein EL, Tuttle RH, Shaw LK, Anstrom KJ, Kong DF

 

Duke Clinical Research Institute, Durham, NC, USA

PCV6

REACHING SIGN CHOLESTEROL TARGETS AND BEYOND: RETROSPECTIVE AUDIT OF TARGETS ACHIEVED THROUGH USE OF ROSUVASTATIN IN A SCOTTISH GENERAL PRACTICE

 

Burnett GR1, Dickson K1, Emmas CE2

 

1Princes Street Surgery, Thurso, Scotland, UK, 2AstraZeneca UK, Luton, UK

PCV7

REACHING AWMSG TARGETS AND BEYOND-A RETROSPECTIVE AUDIT OF TARGETS ACHIEVED THROUGH USE OF ROSUVASTATIN IN WELSH GENERAL PRACTICE

 

Moore RP1, Chapman JR1, Davies EJ1, Davies SH1, Davies N1, Harfoot DA1, Emmas CE2

 

1Towers Surgery, Barry, Wales, UK, 2AstraZeneca UK, Luton, UK

PCV8

THE EFFECTIVENESS OF ROSUVASTATIN COMPARED WITH OTHER STATINS – RESULTS FROM A ROUTINE CLINICAL PRACTICE SETTING IN THE UK

 

Hirsch MW1, O'Donnell JC1, Jansen JP2

 

1AstraZeneca Ltd, Macclesfield, Cheshire, UK, 2Mapi Values, Houten, The Netherlands

PCV9

NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS LEADS TO INCREASED RISK OF HOSPITALIZATIONS FOR ACUTE MYOCARDIAL INFARCTION OR STROKE

 

Breekveldt-Postma NS1, Siiskonen SJ1, Penning-van Beest FJ1, Falvey H2, Vincze G2, Erkens JA1, Herings RM1

 

1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Novartis Pharma AG, Basel, Switzerland

PCV10

COST-EFFECTIVENESS OF A LIFESTYLE INTERVENTION FOR HYPERTENSION: AN OPEN RANDOMISED CONTROLLED TRIAL

 

Martikainen JA1, Kastarinen M2, Puska P3, Nissinen A3

 

1Centre for Pharmaceutical Policy and Economics (CEPPE), Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, 2Kuopio University Hospital, PL 1777, Kuopio, Finland, 3National Public Health Institute, 00300, Helsinki, Finland

PCV11

CLINICAL EFFECTIVENESS OF BETALOC ZOC COMPARED TO METOPROLOL TARTRATE OR CARVEDILOL IN HYPERTENSION TREATMENT.

 

Kawalec P1, Borek E2

 

1Jagiellonian University, Kraków, Poland, 2Astra Zeneca Poland, Warsaw, Poland

PCV12

Withdrawn

 

 

PCV13

EFFECT OF ABSOLUTE REDUCTION IN LDL CHOLESTEROL ON CARDIOVASCULAR EVENTS: DOES FINAL LDL CHOLESTEROL ACHEIVED MATTER?

 

Rahilly CR1, Gaziano J2, Scranton R2

 

1Boston VA Healthcare System, Jamaica Plain, MA, USA, 2VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA

PCV14

ASCOT-LIKE PATIENT PREVALENCE AMONG THE HYPERTENSIVES IN SPAIN

 

Sicras A1, F Bobadilla J2, Moreno R3, Arístegui R2, García M4

 

1Badalona Servicios Asistenciales, Barcelona, Spain, 2Pfizer Spain, Alcobendas, Madrid, Spain, 3Hospital Clinico San Carlos, Madrid, Madrid, Spain, 4Euroclin Institute, Alcobendas, Madrid, Spain

PCV15

ANALYSIS OF PRESCRIBING PATTERNS OF ANTIHYPERTENSIVE AGENTS (AA) BEFORE AND AFTER PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)

 

Brixner D1, Maio V2

 

1The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2Thomas Jefferson University, Philadelphia, PA, USA

PCV16

MAIN CARDIOVASCULAR RISK FACTORS: ASSOCIATION AND CONTROL IN A PRIMARY HEALTHCARE SETTING

 

Sicras A1, Navarro R1, Rejas J2, F Bobadilla J2, García M3, González P2

 

1Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 2Pfizer Spain, Alcobendas, Madrid, Spain, 3Euroclin Institute, Alcobendas, Madrid, Spain

PCV17

PROJECTED IMPACT ON CORONARY HEART DISEASE OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN EUROPEAN PATIENTS WITH TYPE 2 DIABETES

 

Liens D1, Palmer AJ2, Valentine WJ2, Renaudin C1, Roze S2

 

1Merck Santé, Lyon, France, 2CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland

PCV18

OUTCOME OF THIAZOLIDINEDIONE USE IN DISCHARGED DIABETIC PATIENTS WHO WERE HOSPITALIZED FOR HEART FAILURE

 

Chou HY1, Huang WF2, Tsai YW3

 

1National Yang-Ming University, Taipei City, Taiwan, 2National Yang-Ming University, Taipei, Taiwan, 3National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan

PCV19

DISCONTINUED USE OF MYCOPHENOLATE MOFETIL AND GRAFT LOSS IN HEART TRANSPLANT RECIPIENTS

 

Legorreta AP1, Kang N2 , Gilmore AS2, Marehbian J2, Naujoks C3 , Machnicki G3

 

1UCLA School of Public Health, Los Angeles, CA, USA, 2Health Benchmarks, Inc, Woodland Hills, CA, USA, 3Novartis Pharma AG, Basel, Switzerland

Cost Studies

PCV20

FINANCIAL IMPACT OF EPLERENONE USE IN A SPANISH REFERENCE HOSPITAL

 

F Bobadilla J1, García M2

 

1Pfizer Spain, Alcobendas, Madrid, Spain, 2Euroclin Institute, Alcobendas, Madrid, Spain

PCV21

ANTIHYPERTENSIVE DRUG BUDGET IMPACT OF THE ANGIOTENSIN II RECEPTOR BLOCKERS (ARB) IN THE UK

 

Blak BT1, Weir MR1, Simoni-Wastila L1, Shaya FT1, Cooke CE2, Mullins CD1

 

1University of Maryland, Baltimore, MD, USA, 2Pfizer Inc, Ellicott City, MD, USA

PCV22

COST IMPACT OF DIAGNOSTIC IMAGING FOR LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE (PVD)

 

Hay JW1, Scranton R2, Yucel K3, Guo A4, Balzer T4, Gaziano J2

 

1University of Southern California, Los Angeles, CA, USA, 2VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA, 3VA Boston Healthcare System, Boston, MA, USA, 4Berlex Laboratories, Wayne, NJ, USA

PCV23

ECONOMIC BURDEN OF CONTRAST-INDUCED NEPHROPATHY (CIN): IMPLICATIONS FOR PREVENTION STRATEGIES

 

Subramanian S1, Bapat B2, Zyczynski T3, Tumlin J4

 

1RTI International, Waltham, MA, USA, 2RTI Interntional, Research Triangle Park, NC, USA, 3GE Healthcare, Princeton, NJ, USA, 4University of NC and Southeast Renal Associates, Charlotte, NC, USA

PCV24

CARDIOVASCULAR EVENTS REDUCTION AND COST-EFFECTIVENESS OF ATORVASTATIN VERSUS PRAVASTATIN IN SPANISH POPULATION WITH ACUTE CORONARY SYNDROME (ACS)

 

F Bobadilla J1, Checa JC1, Soto J1, García M2, Martínez E1, Hernández G1

 

1Pfizer Spain, Alcobendas, Madrid, Spain, 2Euroclin Institute, Alcobendas, Madrid, Spain

PCV25

COST-EFFECTIVENESS OF CLOPIDOGREL IN MEXICO: WITHIN TRIAL ANALYSIS

 

Jerjes-Sanchez C1, Trujillo A2, Ramos MA3, Hernandez I4, Alvarado R5, Cruz A6, Rangel FJ6, Morales E7

 

1Hospital de Enfermedades Cardiovasculares y Torax-IMSS, Monterrey, Nuevo León, Mexico, 2Hospital General de Zona 57, Tlalnepantla, Mexico, Mexico, 3UMAE CM La Raza, Mexico City, Mexico City, Mexico, 4Hospital Juarez de Mexico, Mexico City, Mexico, Mexico, 5ISSSTE Durango, Durango, Durango, Mexico, 6Hospital PEMEX-Norte, Mexico City, Mexico City, Mexico, 7Cardiometabolic Research Unit, Aguascalientes, Aguascalientes, Mexico

PCV26

COST-EFFECTIVENESS OF CLOPIDOGREL IN MEXICO: A LONG TERM ANALYSIS

 

Jerjes-Sanchez C1, Trujillo A2, Ramos MA3, Hernandez I4, Alvarado R5, Cruz A6, Rangel FJ6, Morales E7

 

1Hospital de Enfermedades Cardiovasculares y Torax-IMSS, Monterrey, Nuevo León, Mexico, 2Hospital General de Zona 57, Tlalnepantla, Mexico, Mexico, 3UMAE CM La Raza, Mexico City, Mexico, 4Hospital Juarez de Mexico, Mexico City, Mexico, 5ISSSTE Durango, Durango, Mexico, 6Hospital PEMEX-Norte, Mexico City, Mexico, 7Cardiometabolic Research Unit, Aguascalientes, Mexico

PCV27

COST-EFFECTIVENESS OF BETALOC COMPARED TO CARVEDILOL IN CARDIAC INSUFFICIENCY AND ARTERIAL HYPERTENSION TREATMENT IN POLAND

 

Kawalec P1, Borek E2

 

1Jagiellonian University, Kraków, Poland, 2Astra Zeneca Poland, Warsaw, Poland

PCV28

COST-EFFECTIVENESS OF INTENSIVE LIPID-LOWERING TREATMENT IN SECONDARY CARDIOVASCULAR PREVENTION IN SPAIN AND GERMANY

 

Taylor DC1, Pandya A1, Thompson D1, Chu P1, Graff J2, LaRosa JC3, Grundy SM4, Wenger NK5, Shepherd J6, Drummond MF7

 

1i3 Innovus, Medford, MA, USA, 2Pfizer, Inc, New York, NY, USA, 3State University of New York Health Science Center, Brooklyn, NY, USA, 4University of Texas, Dallas, TX, USA, 5Emory University School of Medicine, Atlanta, GA, USA, 6University of Glasgow, Glasgow, Scotland, UK, 7University of York, York, Heslington, UK

PCV29

COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN IN TREATING PATIENTS TO LDL-C ATP III GOALS. A MEXICAN PERSPECTIVE OF THE STELLAR TRIAL.

 

Soto H1, Mino D2, Polanco AC1, Gomez G3, Miller P4

 

1Astra Zeneca, Naucalpan, Estado de México, Mexico, 2Instituto Mexicano de Seguro Social, México D.F, México, Mexico, 3Hospital General Dr. Manuel Gea Gonzalez, México D.F, México D.F, Mexico, 4Astra Zeneca, Alderley Park, Alderley Park, UK

PCV30

COST-EFFECTIVENESS OF ROSUVASTATIN FOR CARDIOVASCULAR PREVENTION IN HIGH-RISK POPULATIONS IN SWEDEN

 

Jönsson L1, Ekman M2, Karlsson G3, Brun J3

 

1European Health Economics, London, UK, 2Stockholm Health Economics, Stockholm, Sweden, 3AstraZeneca, Södertälje, Sweden

PCV31

HEALTH ECONOMIC ASSESSMENT OF RAISING HDL-C WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) WHEN ADDED TO STATIN THERAPY IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES: AN ANALYSIS FOR SWEDEN

 

Renaudin C1, Liens D1, Palmer AJ2, Valentine WJ2, Berger W3, Roze S2

 

1Merck Santé, Lyon, France, 2CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland, 3Merck KGaA, Darmstadt, Germany

PCV32

COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION: EUROPEAN MODEL RESULTS BASED ON CLARITY AND COMMIT

 

Berg J1, Lindgren P1, Jönsson B2

 

1Stockholm Health Economics, Stockholm, Sweden, 2Stockholm School of Economics, Stockholm, Sweden

PCV33

COST-EFFECTIVENESS MODEL TO EVALUATE MANAGED VENTRICULAR PACING (MVP) IMPLANTED IN A SPANISH AMBULATORY SURGERY PROGRAM

 

Rodríguez J1, Caro JJ2, Roda J3, Ward A2, Xenakis J2, Malik F4, Bariz H2

 

1Medtronic Iberia, Madrid, Spain, 2Caro Research Institute, Concord, MA, USA, 3General Valencia University Hospital, Valencia, Spain, 4Medtronic Sarl, Tolochenaz, Laussane, Switzerland

PCV34

A COST-EFFECTIVENESS ANALYSIS OF OLMESARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION

 

Lamotte M1, Annemans L2, Van Loy R3, Koch W4

 

1IMS Health, Brussel, Brabant, Belgium, 2IMS Health, Brussels, Belgium, 3Sankyo Pharma, Louvain-La-Neuve, Brabant, Belgium, 4HaaPACS GmbH, Schriesheim, Schriesheim, Germany

PCV35

ESTIMATING LIFETIME COSTS AND LIFE EXPECTANCY ASSOCIATED WITH CARDIOVASCULAR DISEASE IN A SWISS POPULATION WITH AND WITHOUT METABOLIC SYNDROME

 

Ray J1, Darioli R2, Roze S3, Azoulay M4, Bernhardt M4, Valentine WJ5

 

1IMS Health, Allschwil, Basel, Switzerland, 2Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, 3CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland, 4sanofi-aventis (suisse) sa, Meyrin, Geneva, Switzerland, 5CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland

PCV36

A HEALTH ECONOMIC EVALUATION OF CONCOMITANT SURGICAL ABLATION FOR ATRIAL FIBRILLATION

 

Lamotte M1, Annemans L2, Siebert M3

 

1IMS Health, Brussel, Brabant, Belgium, 2IMS Health, Brussels, Belgium, 3St-Jude Medical, Zaventem, Vlaams Brabant, Belgium

PCV37

COST-EFFECTIVENESS OF LONG-TERM TREATMENT OF HYPERTENSION WITH IRBESARTAN VS. LOSARTAN OR NO TREATMENT IN DENMARK

 

Knudsen MS1, Lange M2, Dahl E3

 

1Muusmann Research & Consulting AS, Copenhagen, Denmark, 2Sanofi-aventis, Hoersholm, Denmark, 3Bristol-Myers Squibb, Lyngby, Denmark

PCV38

COST MINIMIZATION ANALYSIS OF BIVALIRUDIN VERSUS HEPARIN PLUS PLANNED ABXICIMAB IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

 

Cequier Á1, Morís C2, Badia X3, Lara N3

 

1Hospital Universitario de Bellvitge. Universidad de Barcelona, Barcelona, Barcelona, Spain, 2Hospital Universitario Central de Asturias, Asturias, Asturias, Spain, 3Health Outcomes Research Europe, Barcelona, Spain

PCV39

PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE II DIABETES A COST-MINIMIZATION ANALYSIS

 

Berto P1, Cremonesi G2

 

1Pbe consulting, Verona, Italy, 2Chiesi Farmaceutici, Parma, Italy

PCV40

A COST-EFFECTIVENESS ANALYSIS OF CARDIAC REHABILITATION AFTER PERCUTANEOUS CORONARY INTERVENTIONS

 

Lamotte M1, Annemans L2, Raskin A3, Hansen D3, Dendale P3

 

1IMS Health, Brussel, Brabant, Belgium, 2IMS Health, Brussels, Belgium, 3Virga Jesse Hospital, Hasselt, Limburg, Belgium

PCV41

A COST CONSEQUENCE ANALYSIS OF THE IMPACT OF JBS 2 ON PATIENTS ELIGIBLE FOR STATIN TREATMENT IN SCOTLAND

 

Shepherd J1, Kingslake SL2

 

1University of Glasgow, Glasgow, Scotland, UK, 2AstraZeneca UK Ltd, Luton, Bedfordshire, UK

PCV42

IMPACT OF VENTRICULAR ARRHYTHMIAS ON HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (AMI)

 

Iyer S1, Ciuryla V1, Wang PF2

 

1Wyeth Research, Collegeville, PA, USA, 2Premier Healthcare Informatics, Charlotte, NC, USA

PCV43

COST ANALYSIS OF TREATMENT WITH NESIRITIDE FOR ACUTE DECOMPENSATED HEART FAILURE IN A BRAZILIAN SETTING

 

Pereira M1, Vianna D2, Bacaltchuk J3, Duchesne I3

 

1Racionale, Sao Paulo, Brazil, 2University of Rio de Janeiro, Rio de Janeiro, Brazil, 3Janssen-Cilag, Sao Paulo, Brazil

PCV44

COMORBIDITIES, COSTS AND THERAPEUTIC GOALS ACHIEVED IN THE SECONDARY PREVENTION OF THE PRIMARY HEALTH CARE

 

Sicras A1, Navarro R1, LLopart López JR1, F Bobadilla J2, García M3, González P2

 

1Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 2Pfizer Spain, Alcobendas, Madrid, Spain, 3Euroclin Institute, Alcobendas, Madrid, Spain

PCV45

COST OF CHRONIC VENOUS INSUFFICIENCY (CVI) IN POLAND

 

Bartminski W, Faluta T, Czech M, Pachocki R

 

Servier Polska, Warszawa, woj. mazowieckie, Poland

PCV46

NON-HOSPITAL COSTS AND NUMBER OF CARDIOVASCULAR RISK FACTORS (CVRF) IN SPANISH HIPERTENSIVE PATIENTS.

 

F Bobadilla J1, Sicras A2, García M3, Soto J1

 

1Pfizer Spain, Alcobendas, Madrid, Spain, 2Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 3Euroclin Institute, Alcobendas, Madrid, Spain

PCV47

DIRECT MEDICAL COSTS FOR TREATMENT OF MILD TO MODERATE HYPERTENSION IN PATIENTS WITH TYPE II DIABETES

 

Berto P1, Cremonesi G2

 

1Pbe consulting, Verona, Italy, 2Chiesi Farmaceutici, Parma, Italy

PCV48

MEDICATION USE AND ASSOCIATED ANNUAL COSTS IN PATIENTS AT RISK OF ATHEROTHROMBOSIS: RESULTS FOR GERMANY, SPAIN AND THE UK FROM THE REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY

 

Mahoney EM1, Wang K1, Bruggenjurgen B2, Bakhai A3

 

1New England Research Institutes, Watertown, MA, USA, 2Charite University Medical Center, Berlin, Germany, 3Barnet & Chase Farm NHS Trust, Barnet, UK

PCV49

COST-UTILITY ANALYSIS USING A MARKOV MODEL TO COMPARE PRESCRIPTION STATINS VERSUS POTENTIAL OVER THE COUNTER STATINS IN USA

 

Gandhi PK1, McGhan WF2, Peterson AM2

 

1University of Florida-Gainesville, Gainesville, FL, USA, 2University of the Sciences in Philadelphia, Philadelphia, PA, USA

PCV50

EFFICACY AND SOCIOECONOMIC RELEVANCE OF HAWTHORN EXTRACT (CRATAEGUS) WS® 1442 IN THE TREATMENT OF NYHA II CHF PATIENTS - RESULTS FROM A PROSPECTIVE THREE-YEAR PHARMACOECONOMIC STUDY

 

Rychlik R1, Ernen C1, Daniel D1, Klapper HG2, Habs M2

 

1Institute of Empirical Health Economics, Burscheid, NRW, Germany, 2Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Baden-Württember, Germany

PCV51

ECONOMIC EVALUATION OF DIAGNOSTIC STRATEGIES IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE (CAD) IN THE UK

 

Ratcliffe A1, Barwell T1, Chambers MG2

 

1Abacus International, BICESTER, OXON, UK, 2GE Healthcare, Buckinghamshire, UK

PCV52

LOSARTAN-BASED VERSUS ATENOLOL-BASED THERAPY IN PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY: AN ECONOMIC EVALUATION OF THE LOSARTAN INTERVENTION FOR ENDPOINT REDUCTION IN HYPERTENSION (LIFE) STUDY FOR GERMANY

 

Krobot KJ1, Carides GW2, Wagner A1, Burke TA3

 

1MSD Sharp & Dohme GmbH, Haar, Germany, 2Merck & Co., Inc, Upper Gwynedd, PA, USA, 3Merck & Co., Inc, Whitehouse Station, NJ, USA

PCV53

COST-UTILITY ANALYSIS OF EPROSARTAN COMPARED TO ENALAPRIL AND RAMIPRIL IN THE TREATMENT OF MODERATE TO SEVERE HYPERTENSION IN SWEDEN

 

Lindgren P1, Schwander B2, Zöllner Y3, Jönsson B4

 

1Stockholm Health Economics, Stockholm, Sweden, 2Analytica International, Loerrach, Germany, 3Solvay Pharmaceuticals GmbH, Hannover, Germany, 4Stockholm School of Economics, Stockholm, Sweden

PCV54

COST-EFFECTIVENESS ANALYSIS OF DIAGNOSTIC METHODS IN THE MANAGEMENT OF PATIENTS WITH SYMPTOMATIC, LOWER LIMB PERIPHERAL ARTERIAL DISEASE.

 

Aguiar-Ibáńez R1, Craig D1, Collins R1, Cranny G1, Burch J1, Wright K1, Berry E2, Gough M3, Kleijnen J4, Westwood M1

 

1Centre for Reviews and Dissemination, York, UK, 2EB Imagistics Ltd, Leeds, UK, 3Leeds General Infirmary, Leeds, UK, 4Kleijnen Systematic Reviews Ltd, York, UK

PCV55

ECONOMIC EVALUATION OF DRUG ELUTING STENTS: COST-UTILITY ANALYSIS

 

Bischof M, Briel M, Bucher HC, Nordmann A

 

University Hospital Basel, Basel, BS, Switzerland

PCV56

ESTIMATION OF THE PRESENCE OF CARDIOVASCULAR EVENTS AND DIRECT COSTS ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AN AMBULATORY SETTING

 

Sicras A1, Navarro R1, F Bobadilla J2, García M3, Soto J2

 

1Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 2Pfizer Spain, Alcobendas, Madrid, Spain, 3Euroclin Institute, Alcobendas, Madrid, Spain

Health Care Use & Policy Studies

PCV57

COSTS ASSOCIATED WITH DRUG USE IN THE NON-ADHERENCE TO CHOLESTEROL MANAGEMENT GUIDELINES FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN AN ELDERLY POPULATION: THE ROTTERDAM STUDY

 

Gumbs PD1, Verschuren WMM2, Mantel-Teeuwisse AK1, De Wit GA2, Hofman A3, Trienekens PH4, Stricker BHC3, De Boer A1, Klungel OH1

 

1Utrecht University, Utrecht, Utrecht, The Netherlands, 2National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 3Erasmus University, Rotterdam, The Netherlands, 4Stichting Trombosedienst en Artsenlaboratorium Rijnmond, Rotterdam, The Netherlands

PCV58

THE ROLE OF ECONOMIC FACTORS IN THERAPEUTIC DECISION MAKING CONCERNING TREATMENT OF CORONARY ARTERY DISEASE IN POLAND

 

Banasiak W1, Jaworski R2, Czech M2, Pachocki R2

 

14th Military Hospital, Wroclaw, Poland, 2Servier Polska, Warsaw, Poland

PCV59

LIPID TESTING AMONG PATIENTS RECEIVING FIRST-EVER STATIN THERAPY IN UK GENERAL PRACTICES

 

Phatak H1, Wentworth C2, Burke TA3

 

1Rutgers University: The State University of New Jersey, Piscataway, NJ, USA, 2Analytic Consulting Solutions, Wakefield, RI, USA, 3Merck & Co., Inc, Whitehouse Station, NJ, USA

PCV60

A CARE MAP FOR CHF IN THE UK

 

Knight CJ

 

Heron Evidence Development Ltd, Letchworth, UK

PCV61

INITIAL PHARMACOTHERAPY FOR PATIENTS WITH DYSLIPIDEMIA IN PRIMARY CARE

 

Luo N1, Zhao 2Z, Liu GG3

 

1National University of Singapore, Singapore, Singapore, 2Eli Lilly, Indianapolis, IN, USA, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PCV62

DRUG USE EVALUATION OF ROSUVASTATIN IN A HONG KONG PUBLIC HOSPITAL

 

Lee VWY, Leung PH, Tomlinson B, Lee KK

 

The Chinese University of Hong Kong, Shatin, Hong Kong, China

PCV63

Withdrawn

PCV64

Withdrawn

PCV65

ECONOMIC APPRAISAL OF THE ANGIOPLASTY PROCEDURES PERFORMED IN 2004 IN A HIGH-VOLUME DIAGNOSTIC AND SURGICAL CARDIOLOGY UNIT

 

Ponzi P1, Di Stasi F1, Manari A2, Guiducci V2, Giacometti P2, Pignatelli G2

 

1Medtronic Italia, Sesto San Giovanni (MI), Italy, 2Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

PCV66

THE VALUE OF MYOCARDIAL PERFUSION SCINTIGRAPHY (MPS) IN CORONARY ARTERY DISEASE (CAD): A REVIEW OF THE ECONOMIC LITERATURE SUBMITTED TO THE UK NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

 

Sidhu MK1, Scott DA1, Vale L2, Chambers MG3

 

1Fourth Hurdle Consulting, London, UK, 2University of Aberdeen, Aberdeen, UK, 3GE Healthcare, Buckinghamshire, UK

PCV67

PROJECTED COST SAVINGS TO THIRD PARTY PAYERS FOR THE YEAR FOLLOWING GENERIC SIMVASTATIN AVAILABILITY IN USA

 

Gandhi PK1, McGhan WF2, Spooner JJ3, Peterson AM2

 

1University of Florida-Gainesville, Gainesville, FL, 2University of the Sciences in Philadelphia, Philadelphia, PA, USA, 3Advanced Concepts Institute, Philadelphia, PA, USA

PCV68

CLOPIDOGREL PATTERNS OF USE IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN 5 EUROPEAN COUNTRIES

 

Smith H1, McCollam PL2, Nasuti P1, Bae JP2

 

1IMS Hospital Group Ltd, Sittingbourne, UK, 2Eli Lilly and Company, Indianapolis, IN, USA

PCV69

RETROSPECTIVE STUDY OF CLOPIDOGREL USE AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) UNDERGOING CORONARY ARTERY BYPASS GRAFT

 

Hauch O1, Doyle J2, Stern L2, Berenson K2, Hendlish S2

 

1AstraZeneca, Wilmington, DE, USA, 2Analytica International, New York, NY, USA

PCV70

MANAGEMENT AND OUTCOMES IN THE CARE OF ATRIAL FIBRILLATION IN GERMANY (MOCA)

 

Bruggenjurgen B1, McBride D2, Willich SN1

 

1Charite University Medical Center, Berlin, Germany, 2Institute for Social Medicine, Epidemiology and Health Economics, Berlin, Germany

PCV71

PHARMACOECONOMIC ANALYSIS OF TREATMENT OF HYPERTENSION IN CLINICAL CENTER OF SERBIA- PHARMACY AND MEDICAL SUPPLY

 

Simic G

 

Clinical Center of Serbia, Belgrade, Serbia and Montenegro

Methods & Concepts

PCV72

ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) FOR MILD TO MODERATE HYPERTENSION: A LITERATURE REVIEW

 

Maniadakis N1, Theodoratou T2, Fragoulakis V3, Hatzikou M2

 

1University hospital of Heraklion, Drosia, Greece, 2Boehringer Ingelheim Ellas, Elliniko, Greece, 3IOVE, Athens, Greece

PCV73

ANALYSIS OF COST AND EFFECTIVENESS DATA USING RANDOM PERMUTATION METHODS

 

Kolm P

 

Christiana Care Health System, Newark, DE, USA

PCV74

COST-EFFECTIVENESS ANALYSIS IN CORONARY ARTERY DISEASE DIAGNOSIS: CHOOSING BETWEEN LABORATORY MARKERS

 

Bogavac-Stanojevic N1, Ivanova Petrova G2, Jelic-Ivanovic Z1

 

1University School of Pharmacy, Belgrade, Serbia, Serbia and Montenegro, 2Medical University, Sofia, Bulgaria, Bulgaria

PCV75

DERIVING COST INPUT VALUES FOR USE IN A MARKOV MODEL FOR EXPLORING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN OVERWEIGHT OR OBESE SUBJECTS

 

McEwan P1, Nicholls C2, Caro JJ3

 

1Cardiff Research Consortium, Cardiff, UK, 2Sanofi-Aventis, Guildford, Surrey, UK, 3Caro Research Institute, Concord, MA, USA

PCV76

THE GERMAN CARDIOMETABOLIC COST DATABASE - A METHODOLOGICAL APPROACH TO ASSESS COST DATA FOR MODELLING COST-EFFECTIVENESS OF TREATMENT REGIMES FOR PATIENTS WITH MULTIPLE CARDIOMETABOLIC RISK FACTORS.

 

Fuchs SM1, Klauss V2, Dieterle C2, Wasem J3, Aidelsburger P1

 

1Carem GmbH, Sauerlach, Germany, 2University of Munich, Munich, Germany, 3University of Duisburg-Essen, Essen, Germany

PCV77

DISCRETE-EVENT-SIMULATION AN APPROACH THAT CHALLENGES TRADITIONAL MODELING METHODS? AN ILLUSTRATION USING DRUG-ELUTING STENTS

 

Jahn B1, Theurl E2, Goeree RA3, Bowen J3, Blackhouse G3, Hopkins R3, Tarride JE3

 

1Innsbruck Medical University, Innsbruck, Austria, 2Leopold-Franzens-University Innsbruck, Innsbruck, Austria, 3McMaster University, Hamilton, ON, Canada

PCV78

TOWARDS A MODELLED ECONOMIC EVALUATION TO IDENTIFY THE OPTIMAL POPULATION FOR SCREENING OF CORONARY ARTERY DISEASE

 

Tilden D1, Pascoe K1, Higashi MK2, Marelli C3, Kennedy L3, Scheijbeler H1, Aristides M1

 

1IMS, London, UK, 2GE Healthcare, Wauwatosa, WI, USA, 3GE Healthcare, Buckinghamshire, UK

PCV79

CLASSIFYING PATIENTS WITH DYSLIPIDEMIA: A LATENT CLASS ANALYSIS

 

Liu GG1, Luo N2, Zhao Z3

 

1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2National University of Singapore, Singapore, Singapore, 3Eli Lilly, Indianapolis, IN, USA

PCV80

DERIVING UTITLITY VALUES FOR USE IN A MARKOV MODEL FOR EXPLORING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN OVERWEIGHT OR OBESE SUBJECTS

 

McEwan P1, Nicholls C2, Getsios D3, Caro JJ3

 

1Cardiff Research Consortium, Cardiff, UK, 2Sanofi-Aventis, Guildford Surrey, UK, 3Caro Research Institute, Concord, MA, USA

PCV81

VALIDATION OF THE MODE OF ADMINISTRATION OF THE MEDICATION COMPLIANCE QUESTIONNAIRE

 

Rosa K1, Fitzgerald KA1, Moller RA2

 

1Mapi Values USA LLC, Boston, MA, USA, 2Pfizer, New York, NY, USA

PCV82

VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATIN-TREATED PATIENTS WITH PERSISTENTLY LOW HDL-C

 

Renaudin C1, Berger W2, Liens D1, Valentine WJ3, Palmer AJ3, Roze S3

 

1Merck Santé, Lyon, France, 2Merck KGaA, Darmstadt, Germany, 3CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Switzerland

Patient Reported Outcomes

PCV83

COMPLIANCE PATTERN OF PHARMACOLOGICAL REGIMENS IN HYPERTENSIVES AND/OR DYSLIPIDEMIC PATIENTS IN AMBULATORY CARE IN A SPANISH POPULATION

 

Sicras A1, Navarro R1, F Bobadilla J2, García M3

 

1Badalona Servicios Asistenciales, Barcelona, Spain, 2Pfizer Spain, Madrid, Spain, 3Euroclin Institute, Alcobendas, Madrid, Spain

PCV84

COMPLIANCE IMPROVEMENTS AND HDL CHOLESTEROL LEVELS IN HYPERTENSIVE PATIENTS IN SPAIN

 

Sicras A1, F Bobadilla J2, García M3

 

1Badalona Servicios Asistenciales, Barcelona, Spain, 2Pfizer Spain, Madrid, Spain, 3Euroclin Institute, Madrid, Spain

PCV85

COMPLIANCE AND PERSISTENCE OF FIXED DOSE VERSUS FREE DOSE COMBINATION THERAPY WITH VALSARTAN AND HCTZ FOR PATIENTS WITH HYPERTENSION

 

Jackson KC1, Brixner D2, Oderda GM3, Oberg B1, Sheng X1, Keskinaslan A4

 

1University of Utah Health Sciences Center, Salt Lake City, UT, USA, 2The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 3University of Utah, Salt Lake City, UT, USA, 4Novartis Pharma, AG, Basel, Switzerland

PCV86

CHARACTERIZATION OF HYPERTENSIVE PATIENTS WHO MIGHT BENEFIT FROM A COMBINATION OF TWO DRUGS IN ONE PILL FOR REDUCTION OF CARDIOVASCULAR RISK

 

Sturkenboom MC1, Van der Hoeven Borgman M2, Van Kints A2, Moller RA3, Fitzgerald K4, Rosa K5, Cramer JA6

 

1Erasmus University Medical Center, Soest, The Netherlands, 2Erasmus University Medical Center, Rotterdam, The Netherlands, 3Pfizer, New York, NY, USA, 4Mapi Values, Boston, MA, USA, 5Mapi Values USA LLC, Boston, MA, USA, 6Yale University School of Medicine, West Haven, CT, USA

PCV87

COMPARING COMPLIANCE AND PERSISTENCE RATES FOR HYPERTENSION, DYSLIPIDEMIA, AND DIABETES MEDICATIONS

 

Cramer JA1, Benedict A2, Muszbek N3, Keskinaslan A4, Khan ZM5

 

1Yale University School of Medicine, West Haven, CT, USA, 2UnitedBiosource Corporation, Budapest, Hungary, 3UnitedBiosource Corporation, London, UK, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals, East Hanover, NJ, USA

PCV88

MEDICATION TREATMENT PATTERNS FOR DYSLIPIDEMIA IN US

 

Zhao Z1, Liu GG2, Luo N3

 

1Eli Lilly, Indianapolis, IN, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3National University of Singapore, Singapore, Singapore

PCV89

THE RELATIONSHIP BETWEEN PATIENT BELIEFS AND ADHERENCE TO CHOLESTEROL-LOWERING MEDICATIONS: IMPLICATIONS FOR DISEASE MANAGEMENT PROGRAMS

 

Hansen LG1, Foley K2

 

1Thomson Medstat, Northwood, NH, USA, 2Thomson Medstat, Philadelphia, PA, USA

PCV90

DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ATRIAL FIBRILLATION: 'AF-QOL'

 

Arribas F1, Ormaetxe JM2, Peinado R3, Llorens MÁ4, Perulero N5

 

1Hospital 12 de Octubre, Madrid, Spain, 2Hospital de Basurto, Bilbao, Spain, 3Hospital La Paz, Madrid, Spain, 43M Healthcare, Madrid, Spain, 5Health Outcomes Research Europe, Barcelona, Spain

PCV91

PSICOMETRIC PROPERTIES OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) IN HIPERTENSIVE PATIENTS

 

Ruíz M1, Pardo A1, Sanz de Burgoa V2, Rejas J2, Soto J2, Suárez C3

 

1Universidad Autónoma de Madrid, Madrid, Spain, 2Pfizer Spain, Madrid, Spain, 3Hospital de La Princesa, Madrid, Spain


EYE

Clinical Outcomes Studies

PEY1

USE OF BAYESIAN NETWORKS TO SPECIFY THE NOCTURNAL INTRA-OCULAR PRESSURE PEAK FROM DAYTIME MEASUREMENTS IN GLAUCOMA PATIENTS

 

Nordmann JP1, Berdeaux G2

 

1Centre Hospitalier National des Quinze-Vingts, Paris, France, 2Alcon France, Rueil-Malmaison, France

PEY2

EFFECTIVENESS OF TRAVOPROST VERSUS DORZOLAMIDE + TIMOLOL FIXED COMBINATION IN FIRST LINE TREATMENT OF GLAUCOMA: ANALYZED FROM THE UK GENERAL PRACTITIONER RESEARCH DATABASE

 

Berdeaux G1, Lafuma A2, Guelfucci F3

 

1Alcon France, Rueil-Malmaison, France, 2Cemka-Eval, Bourd-la-Reine, France, 3Cemka-Eval, Bourg-la-Reine, France

PEY3

POSTERIOR CAPSULAR OPACIFICATION AND ND: YAG LASER TREATMENT AFTER CATARACT SURGERY IN FRANCE: COMPARISON ACCORDING TO INTRAOCULAR LENS WITH SQUARE EDGED OPTIC DESIGN

 

Mimaud V1, Lafuma A2, Koshnood B3, Berdeaux G4

 

1Cemka, Bourg-la-Reine, France, 2Cemka-Eval, Bourd-la-Reine, France, 3Cemka-Eval, Bourg-la-Reine, France, 4Alcon France, Rueil-Malmaison, France

PEY4

EFFECTIVENESS OF BRIMONIDINE VERSUS BRINZOLAMIDE IN TREATMENT OF GLAUCOMA: AN ANALYSIS CONDUCTED ON THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE

 

Berdeaux G1, Lafuma A2, Guelfucci F3

 

1Alcon France, Rueil-Malmaison, France, 2Cemka-Eval, Bourd-la-Reine, France, 3Cemka-Eval, Bourg-la-Reine, France

PEY5

COMPARISON OF PHYSICIAN AND PATIENT REPORTED OUTCOMES OF ADULTS WITH DRY EYE DISEASE (KERATOCONJUNCTIVITIS SICCA) MANAGED OVER TIME IN A PATIENT REGISTRY

 

Steeds CS1, Buchholz P2, Irwin DE3, Figueiredo FC4, Figueiredo MS4

 

1CS Consulting, Motherwell, Scoland, UK, 2Allergan Europe, Ettlingen, Germany, 3University of North Carolina, Chapel Hill, NC, USA, 4Royal Victoria Infirmary, Tyne and Wear, UK

PEY6

INCIDENCE OF POSTERIOR CAPSULAR OPACIFICATION AND ND: YAG LASER TREATMENT AFTER CATARACT SURGERY IN FRANCE: COMPARISON ACCORDING TO INTRAOCULAR LENS WITH SQUARE EDGED OPTIC DESIGN

 

Smith AF1, Boureau C2, Lafuma A3, Mimaud V4, Somlay K5

 

1Alcon Laboratories Ltd, Hemel Hempstead, Herts, UK, 2Ophthalmologist, Paris, France, 3Cemka-Eval, Bourd-la-Reine, France, 4Cemka, Bourg-la-Reine, France, 5Laboratoires Alcon, Rueil Malmaison, France

Cost Studies

PEY7

MODELLING THE HEALTH ECONOMIC IMPACT OF OLOPATADINE COMPARED TO BRANDED AND GENERIC SODIUM CROMOGLYCATE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN THE UK

 

Smith AF1, Clegg J2, Guest JF2

 

1Alcon Laboratories Ltd, Hemel Hempstead, Herts, UK, 2Catalyst Health Economics Consultants, Northwood, Middlesex, UK

PEY8

WHEN IS IT COST-EFFECTIVE TO TREAT OCULAR HYPERTENSION? RESULTS OF A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

 

Stewart WC1, Stewart JA1, Nassar Q1, Mychaskiw MA2

 

1Pharmaceutical Research Network, LLC, Charleston, SC, USA, 2Pfizer Inc, New York, NY, USA

PEY9

ASSESSMENT OF THE COST-EFFECTIVENESS OF TRAVOPROST VERSUS LATANOPROST, AS SINGLE AGENTS FOR GLAUCOMA TREATMENT IN FRANCE

 

Payet S1, Berdeaux G2, Launois R1

 

1REES, Paris, France, 2Alcon France, Rueil-Malmaison, France

PEY10

COST-EFFECTIVENESS OF TWO TREATMENT SEQUENCES IN GLAUCOMA TREATMENT: XALATAN®-XALACOM® VERSUS TRAVATAN®-DUOTRAV®

 

Maurel F1, Le pen C1, Berdeaux G2

 

1Aremis, Neuilly sur Seine, France, 2Alcon France, Rueil-Malmaison, France

PEY11

MODELING THE COST AND CONSEQUENCES OF RESTOR®, A MULTIFOCAL INTRAOCULAR LENS (IOL) IN REFRACTIVE SURGERY IN FRANCE

 

Berdeaux G1, Lafuma A2, Guelfucci F3

 

1Alcon France, Rueil-Malmaison, France, 2Cemka-Eval, Bourd-la-Reine, France, 3Cemka-Eval, Bourg-la-Reine, France

PEY12

MODELING THE COSTS AND CONSEQUENCES OF RESTOR®, A MULTIFOCAL INTRAOCULAR LENS (IOL), AFTER CATARACT SURGERY IN FRANCE

 

Berdeaux G1, Lafuma A2, Guelfucci F3

 

1Alcon France, Rueil-Malmaison, France, 2Cemka-Eval, Bourd-la-Reine, France, 3Cemka-Eval, Bourg-la-Reine, France

PEY13

LAST STAGE GLAUCOMA IN EUROPE: COSTS AND QUALITY OF LIFE OF PATIENTS FROM 4 COUNTRIES

 

Aagren M1, Arnavielle S2, Bron A2, Thygesen J3, Baggesen K4, Azuara-Blanco A5, Neville S5, Buchholz P6

 

1MUUSMANN Research & Consulting, Copenhagen, Denmark, 2University Hospital Dijon, Dijon, France, 3Rigshospitalet, Copenhagen, Denmark, 4County of Northern Jutland, Aalborg SV, Denmark, 5Aberdeen University Hospital, Aberdeen, Scotland, UK, 6Allergan Europe, Ettlingen, Germany

PEY14

BIMATOPROST, LATANOPROST, AND TRAVOPROST FOR THE TREATMENT OF GLAUCOMA: A COST-EFFECTIVENESS ANALYSIS IN SCANDINAVIA USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

 

Stewart WC1, Stewart JA1, Passmore CL1, Mychaskiw MA2

 

1Pharmaceutical Research Network, LLC, Charleston, SC, USA, 2Pfizer Inc, New York, NY, USA

PEY15

LATANOPROST VERSUS TIMOLOL MONOTHERAPY FOR THE TREATMENT OF GLAUCOMA: A COST-EFFECTIVNESS ANALYSIS IN SCANDINAVIA AND THE UK USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

 

Stewart WC1, Stewart JA1, Mychaskiw MA2

 

1Pharmaceutical Research Network, LLC, Charleston, SC, USA, 2Pfizer Inc, New York, NY, USA

PEY16

COST-UTILITY ANALYSIS FOR PEGAPTANIB IN AGE-RELATED MACULAR DEGENERATION IN THE UK: THE IMPACT OF DEMOGRAPHIC AND DISEASE CHARACTERISTICS

 

Wolowacz S1, Roskell N2, Maciver F1, Kelly S3

 

1RTI-Health Solutions, Manchester, Manchester, UK, 2RTi Health Solutions, Manchester, UK, 3Pfizer, Tadworth, Surrey, UK

PEY17

COST-EFFECTIVENESS OF PEGAPTANIB IN AGE-RELATED MACULAR DEGENERATION: IMPACT OF DIFFERENCES BETWEEN US AND UK HEALTH CARE SYSTEMS

 

Javitt J1, Wolowacz S2, Roskell N2, Maciver S2, Kelly S3, Pleil A4, Zlateva G5

 

1Johns Hopkins School of Medicine, Washington, DC, USA, 2RTI-Health Solutions, Manchester, UK, 3Pfizer, Tadworth, Surrey, UK, 4Pfizer Inc, San Diego, CA, USA, 5Pfizer Inc, New York, NY, USA

Health Care Use & Policy Studies

PEY18

CHANGES IN MEDICAL AND SURGICAL TREATMENTS OF GLAUCOMA BETWEEN 1997 AND 2003 IN FRANCE

 

Baudouin C1, Renard JP2, Bron A3, Denis P4, Nordmann JP5, Sellem E6, Kenigsberg PA7, Levrat F8, Solesse De Gendre A8, Rouland JF9

 

1Centre Hospitalier National des Quinze Vingts, PARIS, France, 2Hôpital d’Instruction des Armées du Val de Grâce, Paris, France, 3Hôpital Général, Dijon, France, 4Hôpital Edouard Herriot, Lyon, France, 5Centre Hospitalier National des Quinze-Vingts, Paris, France, 6Centre Ophtalmologique Kleber, Lyon, France, 7PAK Santé, France, Paris, France, 8Pfizer, Paris, France, 9Hôpital Huriez, Lille, France

PEY19

PROSTAGLANDIN AGONIST USE WITH AND WITHOUT ADJUNCTIVE THERAPY FOR THE TREATMENT OF GLAUCOMA: A CANADIAN POPULATION BASED ANALYSIS

 

Iskedjian M1, Walker J2, Desjardins O3, Covert D4, Einarson TR5

 

1PharmIdeas USA Inc, Concord, NC, USA, 2Brock University, Faculty of Business, St-Catherines, ON, Canada, 3PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, 4Alcon Research Ltd, Forth Worth, TX, USA, 5University of Toronto, Toronto, ON, Canada

Methods & Concepts

PEY20

MEASURING CURRENT USE OF OCULAR HYPOTENSIVE THERAPIES: ACCOUNTING FOR RESTART RATES

 

Schwartz GF1, Platt R2, Reardon G3, Mychaskiw MA4

 

1Glaucoma Consultants, Greater Baltimore Medical Center; Wilmer Eye Institute, Johns Hopkins University; University of Maryland, Baltimore, MD, USA, 2McGill University, Montreal, QC, Canada, 3Informagenics, LLC, Worthington, OH, USA, 4Pfizer Inc, New York, NY, USA

PEY21

IMPACT OF BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND RELATED VISUAL IMPAIRMENT ON PATIENTS' QUALITY OF LIFE AND FUNCTIONING: A SURVEY OF FIVE COUNTRIES

 

Xu X1, Zlateva G2, Goss TF1, Buggage R2, Cruess A3

 

1Covance Market Access Services, Gaithersburg, MD, USA, 2Pfizer Inc, New York, NY, USA, 3Dalhousie University, Halifax, NS, Canada

Patient Reported Outcomes

PEY22

MEDICATION ADHERENCE AND HEALTH CARE COSTS WITH INTRODUCTION OF LATANOPROST THERAPY FOR GLAUCOMA IN A MEDICARE MANAGED CARE POPULATION

 

Bhosle MJ1, Balkrishnan R1, Reardon G2, Anderson RT3

 

1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2Informagenics, Worthington, OH, USA, 3Wake Forest University School of Medicine, Winston Salem, NC, USA

PEY23

VISION WITH RESTOR® VERSUS MONOFOCAL INTRAOCULAR LENSES (IOL) AFTER CATARACT SURGERY: RESULTS OF A POOLED ANALYSIS

 

Berdeaux G1, Viala M2, Arnould B2

 

1Alcon France, Rueil-Malmaison, France, 2Mapi Values France, Lyon, France

PEY24

METRIC PROPERTIES OF THE MACDQOL IN FRENCH, GERMAN, ITALIAN, AND AMERICAN POPULATIONS: AN INDIVIDUALISED QOL INSTRUMENT SPECIFIC TO MACULAR DISEASE (MD)

 

Berdeaux G1, Mesbah M2, Bradley C3

 

1Alcon France, Rueil-Malmaison, France, 2Université Pierre et Marie Curie, Paris, France, 3University of London, Egham, UK

PEY25

HEALTH-RELATED QUALITY-OF-LIFE AND UTILITY IN DUTCH GLAUCOMA PATIENTS

 

Van Gestel A, Schouten JS, Webers CA, Beckers HJ, Schrooten MA, Severens JL, Hendrikse F

 

Academic Hospital Maastricht, Maastricht, The Netherlands

PEY26

VISION BENEFIT FROM MULTI-FOCAL INTRAOCULAR LENS (IOL) AFTER CATARACT SURGERY ESTIMATED BY PRINCIPAL COMPONENTS ANALYSIS

 

Berdeaux G1, Viala M2, Arnould B2

 

1Alcon France, Rueil-Malmaison, France, 2Mapi Values France, Lyon, France

PEY27

DEVELOPMENT OF A QUESTIONNAIRE ASSESSING PATIENT SATISFACTION WITH EYE DROPS IN OCULAR HYPERTENSION AND GLAUCOMA

 

Berdeaux G1, Trudeau E2, Vigneux M2

 

1Alcon France, Rueil-Malmaison, France, 2Mapi Values, Lyon, France


NEUROLOGICAL DISORDERS

Clinical Outcomes Studies

PND1

META-ANALYSIS OF THE EFFICACY AND TOLERABILITY OF PRAMIPEXOLE AND ROPINIROLE IN RESTLESS LEGS SYNDROME (RLS)

 

Quilici S1, Nicolas A2, Abrams K3, Martin M1, Lleu PL4, Finnern H5

 

1i3 Innovus, Uxbridge, Middlesex, UK, 2Centre Hospitalier le Vinatier, Bron Cedex, France, 3University of Leicester, Leicester, UK, 4Boehringer Ingelheim France, Reims Cedex, France, 5Boehringer Ingelheim GmbH, Ingelheim, Germany

Cost Studies

PND2

ESTIMATING THE BUDGET IMPACT OF LEVETIRACETAM AS ADJUNCTIVE THERAPY IN CHILDREN WITH REFRACTORY PARTIAL ONSET SEIZURE IN THE UK

 

Heaney D1, Germe M2, Brown M3

 

1National Hospital for Neurology and Neurosurgery, London, UK, 2UCB, Braine-l'Alleud, Belgium, 3UCB, Slough, UK

PND3

COST-EFFECTIVENESS ANALYSIS OF ADD-ON THERAPY IN PARTIAL REFRACTORY EPILEPSY IN MEXICO

 

Constantino-Casas P1, Garcia-Contreras F1, Nevarez-Sida A1, Del Angel-García G2, Rojas-Martínez E2, García-Constantino M2

 

1Mexican Institute of Social Security, México, Distrito Federal, Mexico, 2Instituto Mexicano del Seguro Social, México City, Mexico City, Mexico

PND4

PREGABALIN VS GABAPENTIN IN THE TREATMENT OF NEUROPATHIC PAIN IN ITALY: A COST-EFFECTIVENESS ANALYSIS

 

Pradelli L1, Marchettini P2, Iannazzo S1

 

1Advanced Research Srl, Turin, Italy, 2Istituto Scientifico San Raffaele, Milano, Italy

PND5

TREATMENT OF EARLY PARKINSONIAN PATIENTS WITH RASAGILINE OR ROPINIROLE. WHAT IS THE MOST COST-EFFECTIVE TREATMENT STRATEGY IN FINLAND?

 

Armand C1, Eckert L1, Yrjönen T2

 

1H. Lundbeck A/S, Paris, France, 2Oy H. Lundbeck Ab, Turku, Finland

PND6

RETROSPECTIVE EVALUTION OF THE DOSES OF BOTOX AND DYSPORT IN THE MANAGEMENT OF DYSTONIA - A COST MINIMISATION ANALYSIS

 

Jenkins D1, Grünewald R2, Dorward B2, Girod I3

 

1MORPh Consultancy Ltd, Worcester, Worcestershire, UK, 2Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, 3Allergan Limited, Marlow, Bucks, UK

PND7

PREDICTORS OF HEALTH CARE AND NON-HEALTH COSTS IN PATIENTS WITH REFRACTORY EPILEPSY IN SPAIN: FINDINGS FROM THE LINCE STUDY

 

Rejas J1, Peńa P2, Sancho J3, Rufo M4, Palacios G1, Martínez S5, Masramon X5

 

1Pfizer Spain, Alcobendas, Madrid, Spain, 2Universitary Hospital 12 de Octubre, Madrid, Madrid, Spain, 3General University Hospital, Valencia, Valencia, Spain, 4UniversityHospital "Virgen del Rocio", Sevilla, Sevilla, Spain, 5European Biometrics Institute, Barcelona, Barcelona, Spain

PND8

COST-EFFECTIVENESS OF TREATING RESTLESS LEGS PATIENTS WITH PRAMIPEXOLE COMPARED TO NO TREATMENT IN SWEDEN

 

Lees M1, Roberts G1, Tabberer M1, Björkman J2, Ulfberg J3, Finnern H4

 

1Oxford Outcomes Ltd, Oxford, Oxon, UK, 2Boehringer Ingelheim AB, Stockholm, Sweden, 3Inland Hospital, Division Tynset, Tynset, Norway, 4Boehringer Ingelheim GmbH, Ingelheim, Germany

PND9

COST UTILITY ANALYSIS OF LEVODOPA-CARBIDOPA VS LEVODOPA-CARBIDOPA-ENTACAPONE IN PARKINSON DISEASE IN MEXICO

 

Garcia-Contreras F1, Nevarez-Sida A1, Constantino-Casas P1, Rojas-Martínez E2, García-Constantino M2, Del Angel-García G2

 

1Mexican Institute of Social Security, México, Distrito Federal, Mexico, 2Instituto Mexicano del Seguro Social, México City, Mexico City, Mexico

Health Care Use & Policy Studies

PND10

A FUNCTIONAL ANALYSIS OF THE RELATIONSHIP BETWEEN AGE AND MIGRAINE IN THE UNITED STATES OF AMERICA

 

Victor TW, Barlas S

 

Endo Pharmaceuticals, Chadds Ford, PA, USA

Methods & Concepts

PND11

MODELING LONG-TERM 'REAL WORLD' OUTCOMES OF DISEASE-MODIFYING THERAPY IN RELAPSING-REMITTING ONSET MULTIPLE SCLEROSIS

 

Skedgel C1, Brown MG2, Bhan V1

 

1Dalhousie University, Halifax, NS, Canada, 2Capital Health Nova Scotia, Halifax, NS, Canada

PND12

A LITERATURE REVIEW OF PATIENT-REPORTED OUTOMES (PROS), NEUROPSYCHOLOGICAL AND COGNITIVE INSTRUMENTS IN PARKINSON'S DISEASE

 

Staniek V, Emery MP

 

Mapi Research Trust, Lyon, France

Patient Reported Outcomes

PND13

PSICOMETRIC PROPERTIES OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) IN PATIENTS WITH REFRACTORY EPILEPSY

 

Ruíz M1, Rejas J2, Palacios G2, Pardo A1, Soto J2

 

1Universidad Autónoma de Madrid, Madrid, Spain, 2Pfizer Spain, Madrid, Spain

PND14

TREATMENT OF NEUROPATHIC PAIN IN MULTIPLE SCLEROSIS: A POPULATION BASED WILLINGNESS-TO-PAY ANALYSIS

 

Iskedjian M1, Piwko C1, Desjardins O1, Bereza B1, Jaszewski B2, Einarson TR3

 

1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, 2Bayer Healthcare, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

PND15

RELAPSING-REMITTING MULTIPLE SCLEROSIS (RR-MS) PATIENTS' VALUATION OF MS TREATMENT BENEFITS

 

Narewska J1, Lloyd A1, Dewilde S2, Hass SL3, Miller DW3

 

1United BioSource Corporation, London, UK, 2United BioSource Corporation, Brussels, Belgium, 3Elan Pharmaceuticals Inc, San Diego, CA, USA


OSTEOPOROSIS

Clinical Outcomes Studies

POS1

EFFECT OF COMORBIDITIES ON THE EARLY MORTALITY AFTER FEMORAL NECK FRACTURE IN ELDERLY IN HUNGARY

 

Sebestyén A1, Boncz I1, Tóth F2, Betlehem J2, Nyárády J2, Jeges S2

 

1National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2University of Pécs, Pécs, Hungary

POS2

LOSS OF TREATMENT BENEFIT DUE TO LOW COMPLIANCE WITH BISPHOSPHONATE THERAPY

 

Penning-van Beest FJA1, Van den Boogaard CHA1, Erkens JA1, Olson M2, Herings RMC1

 

1PHARMO Institute, Utrecht, The Netherlands, 2Novartis Pharma AG, Basel, Switzerland

POS3

KAPLAN-MEIER SURVIVAL ANALYSIS OF PATIENTS WITH MEDIAL AND LATERAL FEMORAL NECK FRACTURE OVER 60

 

Sebestyén A1, Boncz I1, Betlehem J2, Nyárády J2, Tóth F2

 

1National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2University of Pécs, Pécs, Hungary

Cost Studies

POS4

COMPARING THE COST-EFFECTIVENESS OF RHBMP-2 IN THE TREATMENT OF OPEN TIBIA FRACTURES IN GERMANY, FRANCE, AND UK

 

Chhabra A1, Bentley A2, Oliver E3, Salaun B4, Greenberg D5, Alt V6

 

1Medtronic Europe Sarl, Tolochenaz, Switzerland, 2Abacus International, Bicester, UK, 3Medtronic Ltd, Watford, UK, 4Medtronic France S.A.S, Boulogne, France, 5Ben-Gurion University of the Negev, Beer-Sheva, Israel, 6University Hospital Giessen-Marburg , Brackenheim, Germany

POS5

AN ECONOMIC EVALUATION OF ZOLEDRONIC ACID TREATMENT IN PAGET'S DISEASE OF BONE IN THE HUNGARIAN HEALTH CARE SETTING

 

Kosa J

 

Novartis Hungary Ltd, Budapest, Pest, Hungary

POS6

ECONOMIC ANALYSIS: IBANDRONATE (BONVIVA®) IV INJECTION FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS (PMO) IN THE UK

 

Cowell W1, Koay A1, Hunjan M2

 

1Roche Products Ltd, Welwyn Garden City, UK, 2GlaxoSmithkline, Middlesex, UK

POS7

COST-EFFECTIVENESS OF RISEDRONATE VS. GENERIC ALENDRONATE: CONSIDERATION OF CALCIUM SUPPLEMENTS

 

Moehrke W1, Pasquale M2, Moeller G1

 

1Procter & Gamble Pharmaceuticals, Schwalbach a.Ts, Germany, 2Procter & Gamble Pharmaceuticals, Mason, OH, USA

POS8

THE SOCIETAL BURDEN OF OSTEOPOROSIS

 

Borgström F

 

European Health Economics, Stockholm, Sweden

POS9

COMPARISON OF THE BURDEN OF ILLNESS OF DISPLACED AND UNDISPLACED FEMORAL NECK FRACTURE AFTER REDUCTION INTERNAL FIXATION

 

Sebestyén A1, Boncz I1, Tóth F2, Fodor B2, Betlehem J2, Nyárády J2

 

1National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2University of Pécs, Pécs, Hungary

Health Care Use & Policy Studies

POS10

OSTEOPOROSIS RELATED HEALTH CARE UTILISATION IN HUNGARY BY THE NATIONWIDE HEALTH INSURANCE DATABASE

 

Gulácsi L1, Boncz I2, Péntek M3, Falusi Z2, Sebestyén A2, Tóth E3, Horváth C4

 

1Corvinus University of Budapest, Budapest, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary, 3Flor Ferenc County Hospital, Kistarcsa, Hungary, 4Semmelweis University, Budapest, Hungary

POS11

EVOLUTION OF THE CONSUMPTION OF BISPHOSPHONATES AND RALOXIFENE FINANCED BY THE SPANISH NATIONAL HEALTH SYSTEM FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

 

Gaspar MD

 

University of Barcelona, Barcelona, Spain

POS12

THE DIFFUSION OF NEW DRUG IN TAIWAN MEDICAL CARE UNDER NATIONAL HEALTH INSURANCE: THE CASE OF COX2

 

Tsai YW1, Huang WF2, Wen YW3, Chen PF3

 

1National Health Research Institutes, Zhunan Town, Taiwan, 2National Yang-Ming University, Taipei, Taiwan, 3National Health Research Institutes, Miaoli County, Taiwan

Methods & Concepts

POS13

THE ESTIMATION OF COST_EFFECTIVENESS THRESHOLDS PRIOR TO THE START OF LARGE CLINICAL STUDIES

 

Van Staa TP1, Cooper C2, Leufkens HG3

 

1General Practice Research Database, London, UK, 2University of Southampton, Southampton, UK, 3Utrecht University, Utrecht, The Netherlands

Patient Reported Outcomes

POS14

QUALITY OF LIFE ACCORDING TO EQ-5D AFTER OSTEOPOROTIC HIP FRACTURE IN POLAND

 

Golicki D1, Sliwka A1, Fijewski G2, Latek M3

 

1Medical University of Warsaw, Warsaw, Poland, 2Medical University of Warsaw, Department of Orthopaedics and Traumatology of Locomotor System, Warsaw, Poland, 3Warsaw School of Economics, Warszawa, Poland

POS15

CHANGES IN THE HEALTH STATUS AFTER FEMORAL NECK FRACTURE MEASURED BY EQ-5D

 

Sebestyén A1, Péntek M2, Boncz I1, Gulácsi L3, Sándor J4, Nyárády J4

 

1National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2Flor Ferenc County Hospital, Kistarcsa, Hungary, 3Corvinus University of Budapest, Budapest, Hungary, 4University of Pécs, Pécs, Hungary

POS16

LONG TERM QUALITY OF LIFE RELATED TO OSTEOPOROTIC FRACTURES; 13-18 MONTHS AFTER FRACTURE

 

Ström O1, Borgström F2, Zethraeus N3, Jönsson B3

 

1Stockholm Health Economics, Stockholm, Uppland, Sweden, 2European Health Economics, Stockholm, Sweden, 3Stockholm School of Economics, Stockholm, Uppland, Sweden

POS17

BASELINE CHARACTERISTICS OF FRENCH POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)

 

Rajzbaum G1, Tcherny S2, Liu Leage S2, Germa C2

 

1Saint Joseph Hospital, Paris, France, 2Lilly France, Suresnes, France


SMOKING

Cost Studies

PSM1

THE HIGH COST OF CIGARETTE SMOKING IN GERMANY IN 2003

 

Neubauer S1, Welte R1, Beiche A2, Koenig HH3, Buesch K1, Leidl R1

 

1GSF-National Research Center for Environment and Health, Neuherberg, Germany, 2General Hospital Laupheim, Laupheim, Germany, 3University of Leipzig, Leipzig, Germany

PSM2

COST-UTILITY ANALYSIS FOR SMOKING CESSATION THERAPY IN JAPAN

 

Igarashi A1, Fukuda T1, Oshima A2, Nakamura M3, Tsutani K1

 

1Tokyo University, Tokyo, Japan, 2Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan, 3Osaka Medical Center for Health Science and Promotion, Osaka, Japan


URINARY/KIDNEY

Clinical Outcomes Studies

PUK1

FACTORS ASSOCIATED WITH OVERACTIVE BLADDER IN MEN AND WOMEN: RESULTS FROM THE EPIC STUDY

 

Irwin DE1, Milsom I2, Reilly K3, Hunskaar S4, Kopp Z3, Herschorn S5, Coyne KS6, Kelleher C7, Artibani W8, Hampel C9, Abrams P10

 

1University of North Carolina, North Carolina, NC, USA, 2Sahlgrenska Academy at Goteborg University, Göteborg, Sweden, 3Pfizer, Inc, New York, NY, USA, 4University of Bergen, Bergen, Norway, 5University of Toronto, Toronto, ON, Canada, 6United BioSource Corporation, Bethesda, MD, USA, 7St. Thomas' Hospital, London, England, UK, 8University of Padova, Padova, Padova, Italy, 9Johannes-Gutenberg-Universität, Mainz, Germany, 10Southmead Hospital, Bristol Urological Institute, Bristol, UK

PUK2

LINKING CNI REGIMEN ADHERENCE TO HOSPITAL DAYS AND HEALTH CARE COSTS

 

Legorreta AP1, Gilmore AS2, Marehbian J2, Naujoks C3, Kilburg A3

 

1UCLA School of Public Health, Los Angeles, CA, USA, 2Health Benchmarks, Inc, Woodland Hills, CA, USA, 3Novartis Pharma AG, Basel, Switzerland

Cost Studies

PUK3

BUDGET IMPACT ANALYSIS OF INCLUDING RENAL REPLACEMENT THERAPY IN THE BENEFIT PACKAGE OF UNIVERSAL COVERAGE IN THAILAND

 

Kasemsup V, Prakongsai P, Tangcharoensathien V

 

International Health Policy Program - Thailand, Nonthaburi, Thailand

PUK4

AN ECONOMIC EVALUATION OF DE NOVO RENAL TRANSPLANT RECIPIENTS USING BRANDED (B-CSA) VS. NON-BRANDED CYCLOSPORINE MODIFIED (NB-CSA)

 

Helderman JH1, Gilmore AS2, Ryskina K2, Legorreta AP3, Naujoks C4, Machnicki G4

 

1Vanderbilt University, Nashville, TN, USA, 2Health Benchmarks, Inc, Woodland Hills, CA, USA, 3UCLA School of Public Health, Los Angeles, CA, USA, 4Novartis Pharma AG, Basel, Switzerland

PUK5

COSTS AND COST-EFFECTIVENESS OF EPOETIN IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY DURING THE PREDIALYSIS PERIOD IN POLAND

 

Niewada M1, Kowalik E2, Jakubczyk M3, Rutkowski B4, Szkultecka-Debek M5

 

1Medical University of Warsaw, Warsaw, Poland, 2Institute of Cardiology, Warsaw, Poland, 3Warsaw School of Economics, Warsaw, Poland, 4Medical University of Gdansk, Gdansk, Poland, 5Roche Polska Sp. z o.o, Warsaw, Poland

PUK6

COST-EFFECTIVENESS OF TREATMENT WITH EPOIETIN ALPHA FOR PATIENTS WITH ANAEMIA DUE TO RENAL FAILURE – THE CASE OF SWEDEN

 

Glenngĺrd AH1, Schön S2, Persson U3

 

1The Swedish Institute for Health Economics, IHE, Lund, Sweden, 2Ryhov County Hospital, Jönköping, Sweden, 3The Swedish Institute for Health conomics, IHE, Lund, Sweden

PUK7

ECONOMIC EVALUATION OF TRANSURETHRAL NEEDLE ABLATION (PROSTIVA®) VS. TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) IN BENIGN PROSTATIC HYPERPLASIA (BPH) IN THE SPANISH SETTING

 

Serrano D1, Rodríguez J1, Darba J2, Restovic G2, Fernandez E3

 

1Medtronic Iberia, Madrid, Spain, 2Universitat de Barcelona, Barcelona, Spain, 3Hospital Ramón y Cajal, Madrid, Spain

PUK8

COST-EFFICACY OF FINASTERIDE, DOXAZOSIN AND THE COMBINATION OF BOTH IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN FRANCE BASED ON THE MTOPS STUDY

 

Lafuma A1, Souchet TP2, Briand Y2, Guelfucci F3

 

1Cemka-Eval, Bourd-la-Reine, France, 2Merck Sharp & Dohme - Chibret, Paris, France, 3Cemka-Eval, Bourg-la-Reine, France

PUK9

COST OF ILLNESS IN ITALIAN WOMEN WITH LUTS FOLLOWED AT UROLOGY CENTRES: THE FLOW STUDY

 

Sgarbi S1, Rizzi CA2, Santini AM2, Prezioso D3, Zattoni F4, Pesce F5, Scarpa RM6, Tubaro A7, Artibani W8

 

1MediData srl, Modena, Italy, 2Boehringer Ingelheim, Milan, Italy, 3University “Federico II”, Naples, Italy, 4Policlinico G. Rossi, Verona, Italy, 5CPO Hospital Ostia, Roma, Italy, 6University of Torino, Turin, Italy, 7S. Andrea Hospital, Rome, Italy, 8University of Padova, Padova, Italy

PUK10

A COMPARATIVE STUDY OF THE ECONOMIC BURDEN OF OVERACTIVE BLADDER AND URINARY URGE INCONTINENCE ACROSS 6 WESTERN COUNTRIES

 

Reeves P1, Irwin DE2, Kopp Z3, Bridge S4, Milsom I5, Kelleher C6, Artibani W7

 

1Fourth Hurdle Consulting Ltd, London, UK, 2University of North Carolina, North Carolina, NC, USA, 3Pfizer, Inc, New York, NY, USA, 4Pfizer Ltd, Tadworth, Surrey, UK, 5Sahlgrenska University Hospital, Göteborg, Sweden, 6Guy's and St Thomas' NHS Trust, London, UK, 7University of Padova, Padova, Italy

PUK11

Withdrawn

 

 

PUK12

DECISION MODEL OF RESOURCE (TIME) SAVINGS GENERATED BY EXTENDED DOSING OF ERYTHROPOIESIS STIMULATING PROTEIN (ESP) FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS

 

Barlev A1, Young S2, Bokhari A3, Roberts K4, Globe D1

 

1Amgen, Thousand Oaks, CA, USA, 2Mid-Atlantic Nephrology Associates, PA, Baltimore, MD, USA, 3WNERTA / Baystate Medical Center, Springfield, MA, USA, 4Research By Design, LLC, Evergreen Park, IL, USA

Health Care Use & Policy Studie 

PUK13

TRENDS IN MEDICATION PRESCRIPTION FOR ANEMIA MANAGEMENT OF CHRONIC KIDNEY DISEASE IN A NATIONALLY REPRESENTATIVE SAMPLE OF OUTPATIENT SETTINGS IN THE UNITED STATES

 

Rasu RS1, Balkrishnan R2

 

1University of Missouri Kansas City, Kansas City, MO, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA

Methods & Concepts

PUK14

A COST-UTILITY ANALYSIS IN A UK SETTING OF CINACALCET FOR SECONDARY HYPERPARATHYROIDISM IN END STAGE RENAL DISEASE.

 

Mealing SJ1, Garside R1, Pitt M1, Anderson R1, D'Sousa R2, Stein K1

 

1Peninsula Medical School, Exeter, Devon, England, 2Royal Devon and Exeter Hospital, Exeter, Devon, England

PUK15

MODELLING COST-EFFECTIVENESS USING A DYNAMIC PRICE PATH WITH GENERIC SUBSTITUTION SCENARIOS: COST-EFFECTIVENESS OF CINACALCET IN UK PATIENTS WITH END-STAGE RENAL DISEASE (ESRD) ON HEMODIALYSIS

 

Maetzel A1, Cangialose C2, Roze S3

 

1Amgen (Europe) GmbH / University of Toronto, Zug, Switzerland, 2Amgen Inc, Thousand Oaks, CA, USA, 3CORE - Center for Outcomes Research, A Unit of IMS, Basel, Switzerland

PUK16

COST-EFFECTIVENESS ANALYSIS OF SOLIFENACIN FLEXIBLE DOSING IN PATIENTS WITH OVERACTIVE BLADDER SYMPTOMS IN FOUR NORDIC COUNTRIES

 

Milsom I1, Wickstrřm J2, Poulsen PB2

 

1Sahlgrenska University Hospital, Göteborg, Sweden, 2Muusmann Research & Consulting AS, Kolding, Denmark

PUK17

USE OF SIMULATION TO CAPTURE THE MULTIFACTORIAL ASPECTS OF RENAL DISEASE

 

Migliaccio-Walle K, Moller J, Huybrechts KF, Caro JJ

 

Caro Research Institute, Concord, MA, USA

Patient Reported Outcomes

PUK18

A MULTICENTRE STUDY OF RENAL TRANSPLANT PATIENTS USING THE SF-36 AND THE END STAGE RENAL DISEASE SYMPTOM CHECK-LIST (ESRD-SCL)

 

Ortega T, Ortega F, Valdés C, Rearch Network on Transplantation (FC

 

Hospital Universitario Central de Asturias, Oviedo, Spain

PUK19

OPEN MULTICENTER STUDY OF HEALTH RE LATED QUALITY OF LIFE BEFORE AND AFTER SOLID ORGAN TRANSPLANTATION (KIDNEY, LIVER, HEART AND LUNG)

 

Ortega T, Ortega F, Valdés C, Research Network on Transplantation RFC

 

Hospital Universitario Central de Asturias, Oviedo, Spain

PUK20

PATIENTS UNDER 65 YEARS OF AGE ON RENAL TRANSPLANT WAITING LISTS SHOW A WORSE PERCEIVED STATE OF HEALTH THAN OLDER ONES

 

Rebollo P1, Ortega F2, Ortega T2, Research Network on Transplantation RFC2

 

1BAP Health Outcomes, Oviedo, Spain, 2Hospital Universitario Central de Asturias, Oviedo, Spain

PUK21

RESEARCH NETWORK ON TRANSPLANTATION: FEMALES ON THE WAITING LIST FOR RENAL TRANSPLANT SHOW A POORER PERCEIVED STATE OF HEALTH THAN DO MALES

 

Rebollo P1, Ortega F2, Ortega T2, Research Network on Transplantation RFC2

 

1BAP Health Outcomes, Oviedo, Asturias, Spain, 2Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

PUK22

COMPARISON OF THE PRO ENDPOINTS FOUND IN LABELING CLAIMES OF URINARY INCONTINENCE DRUGS WITH THOSE RECOMMENDED BY THE CORRESPONDING EMEA NOTE FOR GUIDANCE

 

Caron M1, Emery MP2, Acquadro C3, Marquis P4, Piault E4

 

1Mapi Reserach Trust, Lyon, France, 2Mapi Research Trust, Lyon, France, 3Mapi Resaerch Institute, Lyon, France, 4MAPI VALUES USA, Boston, MA, USA

PUK23

IMPACT OF OVERACTIVE BLADDER ON FREQUENCY OF SEXUAL ACTIVITY AND SEXUAL SATISFACTION IN WOMEN: RESULTS FROM THE EPIC STUDY

 

Irwin DE1, Milsom I2, Reilly K3, Hunskaar S4, Kopp Z3, Herschorn S5, Coyne KS6, Kelleher C7, Artibani W8, Hampel C9, Abrams P10

 

1University of North Carolina, North Carolina, NC, USA, 2Sahlgrenska Academy at Goteborg University, Göteborg, Sweden, 3Pfizer, Inc, New York, NY, USA, 4University of Bergen, Bergen, Norway, 5University of Toronto, Toronto, ON, Canada, 6United BioSource Corporation, Bethesda, MD, USA, 7St. Thomas' Hospital, London, UK, 8University of Padova, Padova, Italy, 9Johannes-Gutenberg-Universität, Mainz, Germany, 10Southmead Hospital, Bristol Urological Institute, Bristol, UK

PUK24

LINGUISTIC VALIDATION OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q), OVERACTIVE BLADDER SHORT FORM QUESTIONNAIRE (OAB-Q SF), AND OAB ASSESSMENT TOOL (OAB- V8) IN 4 LANGUAGES

 

Reilly K1, McKown S2, Gawlicki M3, Coyne KS4

 

1Pfizer, Inc, New York, NY, USA, 2Corporate Translations, Inc, Chicago, IL, USA, 3Corporate Translations, Inc, East Hartford, CT, USA, 4United BioSource Corporation, Bethesda, MD, USA

PUK25

LINGUISTIC VALIDATION OF THE PATIENT PERCEPTION OF BLADDER CONDITION QUESTIONNAIRE (PPBC) IN 10 LANGUAGES

 

Reilly K1, McKown S2, Gawlicki M3, Coyne KS4

 

1Pfizer, Inc, New York, NY, USA, 2Corporate Translations, Inc, Chicago, IL, USA, 3Corporate Translations, Inc, East Hartford, CT, USA, 4United BioSource Corporation, Bethesda, MD, USA

PUK26

LINGUISTIC VALIDATION OF THE OVERACTIVE BLADDER SATISFACTION QUESTIONNAIRE (OAB-S) IN 13 LANGUAGES

 

Reilly K1, McKown S2, Gawlicki M3, Piault E4

 

1Pfizer, Inc, New York, NY, USA, 2Corporate Translations, Inc, Chicago, IL, USA, 3Corporate Translations, Inc, East Hartford, CT, USA, 4Mapi Values, Boston, MA, USA

PUK27

RISK OF LEAKAGES IN DAILY ACTIVITIES, RE-WORKING THE CONCEPTUAL FRAMEWORK

 

Arnould B1, Bosio-Legoux B2, Dard S1, Bresson S3, Costa P4

 

1Mapi Values France, Lyon, France, 2Lilly France, Suresnes, France, 3Contractor for Lilly France, Suresnes, France, 4Carémeau University Hospital, Nîmes, France

PUK28

VALIDATION OF THE PELVIC ORGAN PROLAPSE/URINARY INCONTINENCE SEXUAL FUNCTION QUESTIONNAIRE IN ITALIAN WOMEN. THE GYNAEFLOW STUDY

 

Simoni L1, Lessi P2, Artibani W3, Meschia M4, Cervigni M5, Milani R6, Minini G7, Riva D8, Graziottin A9

 

1MediData srl, Modena, Italy, 2Boehringer Ingelheim, Milan, Italy, 3University of Padova, Padova, Padova, Italy, 4Az. Osp. di Legnano P.O. Magenta - Ostetricia Ginecologia, Magenta, Italy, 5Ospedale S. Carlo di Nancy - Ostetricia Ginecologia, Roma, Italy, 6Ospedale Bassini - Ostetricia Ginecologia, Milan, Italy, 7Az. Osp. Spedali Civili - Struttura Semplice Dipartimentale di Uroginecologia, Brescia, Italy, 8Ospedale di Cantů - Ginecologia, Como, Italy, 9Istituto S. Raffaele, Milan, Italy


9th Annual European Congress Main Pagee

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2009 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.
 
Website design by Eagle Systems USA, Inc.